OncoNano Medicine
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3060 Pegasus Park Dr, Dallas, Texas, 752...Website
www.onconano.comRevenue
$5.6 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About OncoNano Medicine
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple, and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. OncoNano is the first company to advance product candidates using pH as a biomarker for cancer immunotherapy, therapeutic use and intraoperative imaging based on its pH-sensitive micelle technology. The company was founded in 2014 and is headquartered in Southlake, Texas.Explore more
OncoNano Medicine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OncoNano Medicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on OncoNano Medicine recently announced quarterly report
Check out if OncoNano Medicine is spiking on competitors!
OncoNano Medicine, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at OncoNano Medicine
Click to see if OncoNano Medicine had a recent Job posting/layoffs
Check if OncoNano Medicine has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once OncoNano Medicine has new funding data
Product Launch: Get notified when OncoNano Medicine launches new products
Recommended Actions
Reach out to Masked Content who joined OncoNano Medicine as Masked Content
Find 3 more new buyers
Compare Similar Companies to OncoNano Medicine
Compare insights from companies similar to OncoNano Medicine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OncoNano Medicine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OncoNano Medicine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OncoNano Medicine.
OncoNano Medicine financials insights
Gather financial insights about OncoNano Medicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$11.7M
2021
Series B
$50M
Series B
$68.4M
OncoNano Medicine Tech Stack
A closer look at the technologies used by OncoNano Medicine
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Funding
Project
Clinical Operations, Operations, Radiology
Promotion
Executive Move
Board of Directors
Promotion
Executive Move
OncoNano Medicine News & Media
Former TechFW board chair Sorrells named chief operating officer at OncoNano Medicine
OncoNano Medicine, Inc. announces the appointment of Brent Sorrells as Chief Operating Officer. Bringing more than two decades of experience in productOncoNano Medicine To Present a Trials in Progress Poster for ON-5001 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine announced that it will present a Trials in Progress poster at the upcoming 2024 ASCO Annual Meeting.OncoNano Medicine Presents Preclinical Data for ON-BOARD™ IL-12 Program at AACR Annual Meeting 2024
SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine presented preclinical data for its ON-BOARD™ IL-12 program at the AACR Annual Meeting 2024.OncoNano Medicine to Present Late-Breaking Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine today announced a late-breaking research poster presentation at the AACR Annual Meeting 2024.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OncoNano Medicine
Sign Up For FreeTo access detailed company insights
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple, and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. OncoNano is the first comp... Read More
